Download DNB 2015 Dec NUCLEAR MEDICINE III Question Paper

FirstRanker.com

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS

DECEMBER 2015

--- Content provided by​ FirstRanker.com ---

NUCLEAR MEDICINE

PAPER - lll

NM/D/15/24/111

Time : 3 hours

Max. Marks : 100

--- Content provided by​ FirstRanker.com ---

Important instructions:

• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.

--- Content provided by‌ FirstRanker.com ---

• Indicate the question number correctly for the answer in the margin space.
• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

--- Content provided by​ FirstRanker.com ---

1. How would you calculate/prescribe the dose of lodine-131 for the treatment of a patient with Grave's disease? Enumerate the advantages and disadvantages of these methods. (5+5)
2. a) Enumerate various radionuclides useful in bone pain palliation. (4+6)
   b) Samarium — 153 in nuclear medicine practice.
3. a) Clinical applications of PRRNT in adults. (5+5)
   b) Associated technical problems and solutions.

--- Content provided by⁠ FirstRanker.com ---

4. Pre-treatment workup, therapy protocol and post treatment follow up the patients for lodine — 131 MIBG therapy.
5. Decay scheme of: (5+5)
   a) Lu-177
   b) lodine — 131
6. a) Principles of Radio-immunotherapy and its clinical applications (5+5)
   

   --- Content provided by FirstRanker.com ---

   b) HAMA with radionuclide-monoclonal antibodies, strategies to prevent them
7. What is radiosynovectomy? How is it advantageous over conventional methods of treatment? Enumerate the most commonly employed radiopharmaceuticals in radiosynovectomy. (2+3+5)
8. a) What are the current guidelines in management of postoperative medullary thyroid cancer? (5+5)
   b) Novel therapies in I-131 refractory thyroid cancer.
9. Tungsten-188/Rhenium-188(W-188/Re-188) generator and newer therapeutic radiopharmaceuticals labeled with Rhenium-188. (10)

--- Content provided by FirstRanker.com ---

10. a) How would you handle death of a patient in the isolation ward who has been administered 150 mCi of lodine-131 for thyroid cancer 24 hour later? (5+5)
    b) What will be your radiation safety advice/instructions to a young married woman of 30 years age who has been post-operatively administered 130 mCi of 1-131 for papillary thyroid cancer?

POSSESSION / USE OF CELL PHONES / GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL